From Robert Ross at CIDRAP :
" A five-country study from Europe indicates that the use of adjuvanted vaccines against the pandemic H1N1 influenza virus probably did not increase the risk of Guillain-Barre syndrome (GBS), but the investigators could not firmly rule out a slightly greater chance of suffering the paralytic condition.
Writing in BMJ, the European researchers report that the adjusted odds ratio (OR) for GBS in those who were vaccinated was 1.0, indicating no higher risk, but the 95% confidence interval (CI) was 0.3 to 2.7, leaving the possibility open.
"The risk of occurrence of Guillain-Barre syndrome is not increased after pandemic influenza vaccine, although the upper limit does not exclude a potential increase up to 2.7-fold or three excess cases per one million vaccinated people," the report states.
GBS associated with flu vaccination has been a concern since the aborted US swine flu vaccination campaign of 1976, when almost one extra GBS case was reported per 100,000 vaccinations. Since then, studies of seasonal flu campaigns have shown no increase or only a slightly increased risk of 1 to 2 extra cases per million vaccinees, according to an editorial accompanying the BMJ report.
In Europe, the 2009 pandemic triggered the first widespread use of flu vaccines containing adjuvants: GlaxoSmithKline's Pandemrix and Novartis's Focetria, which were the most widely used vaccines there. The public's unfamiliarity with adjuvants has been cited as a factor in the generally low vaccine uptake during the pandemic in Europe. Adjuvants have not been used in US flu vaccines.
The European study was a case-control investigation conducted in Denmark, France, the Netherlands, Sweden, and the United Kingdom by the Vaccine Adverse Events Surveillance & Communication (VAESCO) consortium. The study period was November 2009 through March 2010."
Showing posts with label GBS. Show all posts
Showing posts with label GBS. Show all posts
Thursday, July 14, 2011
Thursday, March 10, 2011
New Zealand : Insights into rare disorder at NZ conference
Via Scoop :
" International expert to give medical insights into rare disorder at NZ conference
A world authority on Guillain-Barré Syndrome will headline a conference in the capital late April devoted to discussion around the rare disorder and its related neuropathies.
"Understanding Guillain-Barré Syndrome and CIDP" is the fifth national conference organised by the Guillain-Barré Syndrome Support Group of New Zealand. It will be held from 29 April to 1 May 2011 at the Brentwood Hotel in Kilbirnie, Wellington.
The biennial conference is for people with Guillain-Barré Syndrome (GBS) and its variants such as Miller-Fisher Syndrome, acute motor axonal neuropathy (AMAN) and others as well as patients with chronic disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and related disorders."
" International expert to give medical insights into rare disorder at NZ conference
A world authority on Guillain-Barré Syndrome will headline a conference in the capital late April devoted to discussion around the rare disorder and its related neuropathies.
"Understanding Guillain-Barré Syndrome and CIDP" is the fifth national conference organised by the Guillain-Barré Syndrome Support Group of New Zealand. It will be held from 29 April to 1 May 2011 at the Brentwood Hotel in Kilbirnie, Wellington.
The biennial conference is for people with Guillain-Barré Syndrome (GBS) and its variants such as Miller-Fisher Syndrome, acute motor axonal neuropathy (AMAN) and others as well as patients with chronic disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and related disorders."
Wednesday, January 19, 2011
Hong Kong : CHP investigates a GBS suspected case
Another media statement from Hong Kong's CHP :
" In response to media enquiry, the Centre for Health Protection (CHP) of the Department of Health (DH) confirmed today (January 18) that a report from Queen Mary Hospital (QMH) of a suspected case of Guillain Barre Syndrome (GBS) affecting an 81-year old woman with history of influenza vaccination was received today.
The patient, who has underlying medical conditions, received an influenza vaccination at a government out-patient clinic on December 22, 2010 and developed bilateral lower limb weakness on December 29, seven days after the vaccination. She was admitted to QMH on January 14 and is currently in stable condition.
A spokesman for the CHP said that further investigations are being carried out to ascertain the diagnosis, including for GBS and other neurological conditions."
" In response to media enquiry, the Centre for Health Protection (CHP) of the Department of Health (DH) confirmed today (January 18) that a report from Queen Mary Hospital (QMH) of a suspected case of Guillain Barre Syndrome (GBS) affecting an 81-year old woman with history of influenza vaccination was received today.
The patient, who has underlying medical conditions, received an influenza vaccination at a government out-patient clinic on December 22, 2010 and developed bilateral lower limb weakness on December 29, seven days after the vaccination. She was admitted to QMH on January 14 and is currently in stable condition.
A spokesman for the CHP said that further investigations are being carried out to ascertain the diagnosis, including for GBS and other neurological conditions."
Thursday, June 3, 2010
CDC: GBS risk similar for H1N1 and seasonal flu vaccines
From Lisa Schnirring at CIDRAP, an interesting article :
" Jun 2, 2010 : The risk for the paralytic condition called Guillain-Barre syndrome (GBS) in people who received pandemic H1N1 influenza vaccine was about the same as the risk among those who receive seasonal flu shots, according to preliminary findings released today by the US Centers for Disease Control and Prevention (CDC).
GBS is a rare side effect of illness or vaccination and was linked to the 1976 swine flu vaccine. Today's preliminary analysis from the CDC's Emerging Infections Program (EIP) suggests there were 0.8 excess cases of GBS per 1 million vaccinations, whereas surveillance for the 1976 pandemic vaccine showed about 10 excess cases per 1 million vaccinations. The CDC published the findings in an early-release edition of Morbidity and Mortality Weekly Report (MMWR).
The CDC's EIP, a collaboration between state health departments and academic centers, conducts disease surveillance in 10 states. Today's analysis covers patients who were hospitalized with GBS after September 30, 2009, just as the vaccine launched. Researchers interviewed patients who met the GBS classification definition by phone to gather more information about their medical and vaccination history. "
" Jun 2, 2010 : The risk for the paralytic condition called Guillain-Barre syndrome (GBS) in people who received pandemic H1N1 influenza vaccine was about the same as the risk among those who receive seasonal flu shots, according to preliminary findings released today by the US Centers for Disease Control and Prevention (CDC).
GBS is a rare side effect of illness or vaccination and was linked to the 1976 swine flu vaccine. Today's preliminary analysis from the CDC's Emerging Infections Program (EIP) suggests there were 0.8 excess cases of GBS per 1 million vaccinations, whereas surveillance for the 1976 pandemic vaccine showed about 10 excess cases per 1 million vaccinations. The CDC published the findings in an early-release edition of Morbidity and Mortality Weekly Report (MMWR).
The CDC's EIP, a collaboration between state health departments and academic centers, conducts disease surveillance in 10 states. Today's analysis covers patients who were hospitalized with GBS after September 30, 2009, just as the vaccine launched. Researchers interviewed patients who met the GBS classification definition by phone to gather more information about their medical and vaccination history. "
Subscribe to:
Posts (Atom)